Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta-1b biosimilar - Amega Biotech/Actover Pharmaceutical

Drug Profile

Interferon beta-1b biosimilar - Amega Biotech/Actover Pharmaceutical

Alternative Names: Actoferon

Latest Information Update: 14 May 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amega Biotech
  • Developer Actover Pharmaceutical; Amega Biotech
  • Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 14 Aug 2013 Investigation in Multiple sclerosis in Argentina (SC)
  • 01 Jan 2013 Launched for Multiple sclerosis in Iran (SC)
  • 20 Oct 2011 Actover Pharmaceutical initiates enrolment in a phase III trial for Multiple sclerosis in Iran (IRCT2013030512398N2)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top